Charles River Laboratories (NYSE: CRL) reported Q1 EPS of $2.27, $0.21 better than the analyst estimate of $2.06. Revenue for the quarter came in at $1.01 billion versus the consensus estimate of $992.31 million.

GUIDANCE:

Charles River Laboratories sees FY2024 EPS of $10.90-$11.40, versus the consensus of $11.02.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.